User experienced scarring from microneedling at fast speed and paused treatment for 3-4 weeks to recover. Advice given includes waiting a full month for recovery to avoid scars.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
A user shared their experience with hair loss treatment using finasteride (1mg) and minoxidil (1ml), noting significant shedding phases but hoping for improvement. Shedding is a common synchronized effect of the treatment, which may desynchronize over time, potentially taking over 5 years.
The conversation is about DIY Dutasteride mesotherapy for hair loss, focusing on creating an injectable treatment to target the scalp and limit side effects. The user seeks feedback on enhancing the treatment with additional ingredients.
The conversation is about hair loss treatment progress using 2.5mg oral Minoxidil daily, derma rolling weekly, and Ketoconazole shampoo thrice weekly, with plans to add oral Dutasteride. Users discuss the potential benefits and timing of using Dutasteride for hair recovery.
The conversation discusses Peptonix microneedling, a copper peptide serum, as a potential hair loss treatment. Users compare it to finasteride and minoxidil, noting side effects and personal experiences with these treatments.
The conversation is about the order of applying hair loss treatments, specifically The Ordinary serum and Zix. The user is unsure which to apply first due to the alcohol content in Zix.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.
A user shared their hair loss progress after 2 years of finasteride and 1 year of minoxidil, along with occasional microneedling and regular exercise. They experienced initial shedding but saw significant improvement after 4 months.
Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
User shared 2-year hair loss progress using finasteride 3 times a week and 5 mg oral minoxidil daily. Another user praised the results as a complete recovery.
The conversation discusses hair loss treatments, specifically comparing Dr. Pen and Derminator for hair growth. The user is seeking advice on affordable options due to a low income.
The user is comparing the effectiveness of Maxogen-X and Happy Head topical products for treating hair loss. They note that Maxogen-X causes less flaking and dryness but are concerned about its absorption and overall effectiveness compared to Happy Head.
A user discusses their rapidly receding hairline and a prescribed topical solution containing 7% Minoxidil, 0.1% Finasteride, and 3% biotinoyl tripeptide. The solution is a custom compound from their dermatologist, costing $50 for a one-month supply.
The conversation discusses the challenges and experiences of using minoxidil, finasteride, and dutasteride for hair loss, focusing on the shedding phase and its impact on hair appearance. Users share their personal experiences, side effects, and hopes for improvement, with some considering or having undergone hair transplants.
The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
A user shared a two-year update on their hair loss treatment using dutasteride (0.5mg/day), minoxidil (Kirkland topical foam 2x/day), a 1.5mm derma roller every other week, and a daily multivitamin with biotin. They reported significant hair regrowth with no side effects, emphasizing the importance of consistency and a healthy lifestyle.
Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.
A humorous discussion about a scalp massager used in a barber shop, with no mention of specific hair loss treatments like Minoxidil, finasteride, or RU58841. The massager is described as pleasurable but not a treatment for hair loss.
The user achieved significant hair regrowth in 2.5 months using 2.5mg oral minoxidil, 1mg finasteride, weekly microneedling, and ketoconazole shampoo. Microneedling with a derma stamp was particularly effective, and the user also uses topical minoxidil at night.
The conversation discusses using minoxidil, vitamins, and microneedling for hair loss treatment over two months. Users inquire about the specific vitamins used and the ease of microneedling.
Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.